IQVIA Holdings (IQV) is trending favorably in investment circles as observed from recent activities. Several asset management firms, including
Neo Ivy Capital Management, Dimensional Fund Advisors LP, and
South Dakota Investment Council, have increased their shares. Similarly, three reputable rating agencies,
Barclays, RBC Capital, and
Morgan Stanley, have expressed bullish sentiments despite lowering the price target.
Jim Cramer has also praised the company though expressed uncertainty about the current stock's suitability. Amid concerns around AI disruption, the stock's price declined recently but demonstrated a week-on-week rise of 7% and a post-earnings increase of 9.9%. Additionally, its valuation has been assessed favorably following the fourth-quarter results release. Contrarily, it was reported that
Laurel Wealth Advisors LLC reduced their holdings while the company's share price volatility and cash flow issues were also emphasized. The biopharmaceutical services provider's
CEO is slated to speak at the 2026 Global Healthcare Conference, and it has signed an agreement to acquire drug discovery assets from Charles River Laboratories while releasing its 2025 Sustainability Report.
Iqvia Holdings IQV News Analytics from Thu, 17 Jul 2025 07:00:00 GMT to Sat, 07 Mar 2026 11:58:25 GMT -
Rating 5
- Innovation 2
- Information 7
- Rumor -2
